tiprankstipranks
Trending News
More News >

Actinogen Medical Advances Alzheimer’s and Depression Treatment with Xanamem

Story Highlights
Actinogen Medical Advances Alzheimer’s and Depression Treatment with Xanamem

Confident Investing Starts Here:

The latest update is out from Actinogen Medical Limited ( (AU:ACW) ).

Actinogen Medical announced that its CEO, Dr. Steven Gourlay, will present at the ASX small & mid-caps conference, discussing their novel drug Xanamem, which targets brain cortisol to slow Alzheimer’s progression and treat depression. The company is advancing its pivotal Phase 2b/3 trial for Alzheimer’s and has shown promising results in a Phase 2a trial for depression, highlighting Xanamem’s potential impact on the treatment landscape for these conditions.

More about Actinogen Medical Limited

Actinogen Medical is an ASX-listed biotechnology company focused on developing novel therapies for neurological and neuropsychiatric diseases linked to dysregulated brain cortisol. Their lead compound, Xanamem, is being developed as a treatment for Alzheimer’s Disease and Depression, with potential future applications in Fragile X Syndrome and other conditions. The company aims to address the substantial unmet medical need for improved treatments for cognitive dysfunction and behavioral abnormalities associated with these diseases.

YTD Price Performance: 25.00%

Average Trading Volume: 75,000

Technical Sentiment Signal: Sell

Current Market Cap: $66.98M

Learn more about ACW stock on TipRanks’ Stock Analysis page.

Disclaimer & Disclosure

Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.

Report an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1